Piper Sandler Adjusts CIGNA's Price Target
Recently, Piper Sandler raised its price target for CIGNA Corporation (NYSE: CI) to $394, up from $392, while retaining an Overweight rating on the stock. This revision comes on the heels of CIGNA's impressive third-quarter results, which revealed an adjusted earnings per share (EPS) that exceeded expectations, thanks largely to the performance of its pharmacy segment.
CIGNA's Strong Third-Quarter Performance
CIGNA's third-quarter financial report showcased its resilience amidst various challenges, such as the divestment of certain assets and headwinds in its Evernorth division. Despite these hurdles, the company maintained its adjusted earnings guidance for the year ahead, displaying a confident outlook on its financial trajectory.
Future Earnings Growth Projections
The healthcare leader is forecasting over a 10% growth in consolidated adjusted EPS for 2025. This outlook aligns well with its long-term growth targets of 10% to 14%. Piper Sandler's continued Overweight rating underscores its belief in CIGNA's capabilities to meet these ambitious goals.
Price Target Based on Earnings Multiples
The updated price target is based on maintaining a consistent multiple of 12.5x CIGNA’s estimated adjusted EPS for 2025, with slight upward adjustments factoring in the company's strong performance in Q3. According to Piper Sandler's analysts, CIGNA demonstrated notable resilience and potential for sustained growth.
Recent Financial Highlights
In the latest report, CIGNA showcased a robust performance with revenues totaling $63.7 billion and an adjusted EPS of $7.51. The company anticipates at least a 10% growth in EPS for 2025, supported by new client relationships and biosimilar offerings. Meanwhile, Jefferies maintained a Buy rating on CIGNA, albeit with a lowered price target of $406, down from the previous $422.
Adapting to Industry Changes
This adjustment reflects CIGNA's potential responses to market developments and its overall financial performance. The company's Evernorth segment is expected to grow significantly in the fourth quarter, which is essential for meeting the aforementioned financial objectives.
Impact of Asset Sales
Moreover, CIGNA's pending sale of its Medicare segment to HCSC, expected to close soon, aims to facilitate substantial share repurchases. This strategic move comes despite challenges that include reduced net investment income and administrative costs stemming from the Medicare sale. Nevertheless, CIGNA has reaffirmed a full-year EPS forecast of at least $28.40 for 2024.
Investing Insights and Financial Stability
CIGNA Corporation's recent achievements, coupled with Piper Sandler's encouraging outlook, are echoed by market data showcasing the company's capital standing at $86.77 billion. CIGNA's revenue has seen an impressive 21.0% increase over the past year and a staggering 28.02% growth since Q3.
Shareholder Friendly Policies
Investors should note CIGNA's history of dividend payments, having maintained this practice for 43 years while increasing payouts over the last four years. This consistency in dividends is a testament to CIGNA's strong financial performance and aligns with Piper Sandler's favorable outlook.
Valuation and Profitability Insights
CIGNA's stock trades at an adjusted P/E ratio of 18.99, suggesting a fair valuation given its growth potential. Furthermore, financial projections indicate that CIGNA is likely to remain profitable, bolstering its reputation among investors.
Frequently Asked Questions
What is the new price target for CIGNA set by Piper Sandler?
Piper Sandler has raised its price target for CIGNA to $394 from $392.
Why did CIGNA's price target get revised?
The price target revision followed CIGNA's strong financial performance in its third-quarter earnings report.
What growth does CIGNA predict for its EPS in 2025?
CIGNA is projecting over 10% growth in consolidated adjusted EPS for the year 2025.
How has CIGNA performed financially recently?
CIGNA reported revenue of $63.7 billion and an adjusted EPS of $7.51 in its latest quarterly report.
What does Piper Sandler's Overweight rating indicate?
The Overweight rating indicates Piper Sandler's positive outlook on CIGNA's potential for achieving robust growth targets.
